Recent studies demonstrated that treating patients with low doses of recombinant IL-2 was one of the ways to influence the course of SLE; such treatment led to the normalization of Treg cell functions and Tfr/Tfh balance, decreased formation of autoantibodies against dsDNA, and improved renal condition; furthermore, the restoration of the Tfr/Tfh ratio in SLE patients by the IL-2 therapy has been established and previously shown to be critical for maintaining immune tolerance and preventing autoantibody production[52–53]. The gene discussed is TFRC; the disease is systemic lupus erythematosus.